References

diaendo

Сахарный диабет

Diabetes mellitus

2072-03512072-0378

Endocrinology research centre

10.14341/DM20142105-115

diaendo-6581

Research Article

Детская диабетология

Pediatric diabetology

Лантус, первый беспиковый аналог базального инсулина ? 10-летний опыт применения у детей и подростков

Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents

Кураева

Тамара Леонидовна

Kuraeva

Tamara Leonidovna

доктор медицинских наук, профессор, заведующая отделением сахарного диабета Института Детской эндокринологии

MD, PhD, Professor, Head of the Pediatric Diabetes Department in Pediatric Endocrinology Institute

andrew-135@yandex.ru

Институт детской эндокринологииФГБУ Эндокринологический Научный ЦентрРоссияEndocrinology Research Centre, MoscowRussian Federation

2014

10052014

172105115

2014

Кураева Т.Л.

Kuraeva T.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.dia-endojournals.ru/jour/article/view/6581

Обзор посвящен анализу данных литературы, включая собственные данные, по результатам клинических исследований эффективности и безопасности применения инсулина гларгин (Лантус?) у детей и подростков, а также особенностям управления диабетом 1 типа у данной возрастной категории пациентов, в том числе проблеме снижения частоты гипогликемий при сохранении адекватного гликемического контроля. Рассмотрены также отдельные проблемы в управлении диабетом у детей и подростков, такие как роль гликемического контроля в развитии сосудистых осложнений, гипогликемии, вариабельность гликемии. Представленные данные свидетельствуют о высокой эффективности инсулина Лантус в отношении компенсации сахарного диабета, включая снижение частоты гипогликемий и вариабельности гликемического профиля, о безопасности его применения у детей и подростков, включая детей первых лет жизни, о повышении качества жизни пациентов и их родителей.

This review analyses existing literature, including authors' own data, describing the results of clinical trials which assess safety and efficacy of insulin Glargine (Lantus?) in children and adolescents, as well as peculiar features of T1D management in this age group, including the challenge of reducing the rate of hypoglycemia while maintaining adequate glycemic control. The article also discusses various issues in T1D management in children and adolescents, including the role of glycemic control in development of vascular complications, hypoglycemia and the variability of glycemia. The data confirm the high efficacy of Lantus insulin in respect to metabolic control, including the decrease in the incidence of hypoglycemia and in variability of glycemic profile, the safety of its clinical use in treatment of children, including young children, and adolescents, as well as its ability to improve the quality of life for patients and their parents.

сахарный диабет 1 типадети и подросткиинсулин гларгин (Лантус)гликемический контрольбезопасность

T1Dchildren and adolescentsinsulin Glargineglycemic controlsafety

Sanofi

References1

Williams RM, Dunger DB. Insulin treatment in children and adolescents. Acta Paediatrica 2004;93(4):440-446. Available from: http://doi.wiley.com/10.1080/08035250410024934 doi: 10.1080/08035250410024934.

Петеркова ВА. Сахарный диабет у детей и подростков: к 90-летию введения в клиническую практику инсулина. Фарматека, 2012; 236(3): 67-74.[Peterkova VA. Diabetes In Children And Adolescents: To The 90th Anniversary Of The Introduction Of Insulin In Clinical Practice. Farmateka. 2012; 236(3):67-74.]

Diabetes Control and Complications Trial Research Group.The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med 1993;329(14):977-986. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199309303291401 doi: 10.1056/NEJM199309303291401.

Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. The Journal of Pediatrics 1994;125(2):177-188. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022347694701903 doi: 10.1016/S0022-3476(94)70190-3.

White NH, Cleary PA, Dahms W. Beneficial effects of intensive therapy of diabetes during adolescence: Outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). The Journal of Pediatrics 2001;139(6):804-812. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022347601604542 doi: 10.1067/mpd.2001.118887.

Danne T, Mortensen HB, Hougaard P, Lynggaard H, Aanstoot HJ, Chiarelli F, et al. Persistent Differences Among Centers Over 3 Years in Glycemic Control and Hypoglycemia in a Study of 3,805 Children and Adolescents With Type 1 Diabetes From the Hvidore Study Group. Diabetes Care 2001;24(8):1342-1347. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.24.8.1342 doi: 10.2337/diacare.24.8.1342.

Hanas R, Donaghue KC, Klingensmith G, Swift PGF. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Pediatric Diabetes 2009;10(12):1-2. Available from: http://doi.wiley.com/10.1111/j.1399-5448.2009.00577.x doi: 10.1111/j.1399-5448.2009.00577.x.

Андрианова ЕА, Александрова ИИ, Максимова ВП, Болотская ЛЛ, Ширяева ТЮ, Светлова ГН, и соав. Оценка степени компенсации углеводного обмена и распространённости диабетических осложнений у детей в возрасте до 14 лет в Российской федерации. Сахарный диабет, 2007; (1): 24-29.[Andrianova EA, Aleksandrova II, Maksimova VP, Bolotskaya LL, Shiryaeva, T Yu, , Svetlova GN, et al. Otsenka stepeni kompensatsii uglevodnogoobmena i rasprostranennosti diabeticheskikhoslozhneniy u detey v vozrastedo 14 let v Rossiyskoy Federatsii. Diabetes mellitus 2007; (1):24-29.] Available from: http://endojournals.ru/index.php/dia/article/view/5910 doi: 10.14341/2072-0351-5910.

Андрианова Е.А., Т.Ю.Ширяева, Александрова И.И., Сунцов Ю.И. Оценка степени метаболической компенсации и распространенности диабетических осложнений в Российской популяции детей и подростков (Итоги проекта «Скрининг осложнений сахарного диабета и оценка лечебной помощи больным). Сахарный диабет, 2009; 3: 37-42.[Andrianova E, Aleksandrova I, Shiryaeva T, Suntsov Y. Evaluation of the degree of metabolic compensation and prevalence of diabetic complications in a Russian population of childrenand adolescents (results of the «Screening for diabetic complications and assessment of medical aid to diabetic patients» Project). Diabetes mellitus. 2009;(3):37-42. doi: 10.14341/2072-0351-5450 ]

Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I, Gale EA, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 1999;22(3):495-502. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.22.3.495 doi: 10.2337/diacare.22.3.495.

Marrero DG, Guare JC, Vandagriff JL, Fineberg NS. Fear of Hypoglycemia in the Parents of Children and Adolescents With Diabetes: Maladaptive or Healthy Response. The Diabetes Educator 1997;23(3):281-286. Available from: http://tde.sagepub.com/cgi/doi/10.1177/014572179702300306 PubMed PMID: 9257618. doi: 10.1177/014572179702300306.

Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, et al. The Impact of the Diabetes Control and Complications Trial and Humalog Insulin on Glycohemoglobin Levels and Severe Hypoglycemia in Type 1 Diabetes. Diabetes Care 2001;24(3):430-434. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.24.3.430 PubMed PMID: 11289463. doi: 10.2337/diacare.24.3.430.

Amin R, Ross K, Acerini CL, Edge JA, Warner J, Dunger DB. Hypoglycemia Prevalence in Prepubertal Children With Type 1 Diabetes on Standard Insulin Regimen: Use of Continuous Glucose Monitoring System. Diabetes Care 2003;26(3):662-667. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.26.3.662 PubMed PMID: 12610018. doi: 10.2337/diacare.26.3.662.

Murphy NP, Ford-Adams M, Keane SM. Prolonged QT interval during spontaneous nocturnal hypoglycemia in children and adolescents with type 1 diabetes. Diabetes 2002;51(Suppl 2):8-OR,A2.

Лаптев ДН, Рябыкина ГИ, Соболев АВ, Кириллов КК,Сеид-Гусейнов АА, и соав. Связь гликемии и длительности интервала QT с двигательной активностью у детей и подростков, больных сахарным диабетом 1 типа. Проблемы эндокринологии. 2010; 6(56): 24-31.[Laptev DN, Riabykina GV, Sobolev AV, Kirillov KK, Seid-Guseĭnov AA. The relationship between the level of glycemia, the length of the QT-interval, and locomotor activity in children and adolescents presenting with type 1 diabetes mellitus. Probl. endokrin 2010;56(6):24-31.] Available from: http://endojournals.ru/index.php/probl/article/view/4721 doi: 10.14341/probl201056624-31.

Edge JA, Ford-Adams ME, Dunger DB. Causes of death in children with insulin dependent diabetes 1990-96. Archives of Disease in Childhood 1999;81(4):318-323. Available from: http://adc.bmj.com/cgi/doi/10.1136/adc.81.4.318 PubMed PMID: 10490436. doi: 10.1136/adc.81.4.318.

Perantie DC, Lim A, Wu J, Weaver P, Warren SL, Sadler M, et al. Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatr Diabetes 2008;9(2):87-95. Available from: http://doi.wiley.com/10.1111/j.1399-5448.2007.00274.x doi: 10.1111/j.1399-5448.2007.00274.x.

Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of Severe Hypoglycemia. Diabetes Care 2007;30(6):1370-1373. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc06-1386 PubMed PMID: 17363757. doi: 10.2337/dc06-1386.

Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J, et al. Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes. JAMA 2006;295(14):1681-1687. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.295.14.1681 PubMed PMID: 16609090. doi: 10.1001/jama.295.14.1681.

Brownlee M. The Pathobiology of Diabetic Complications: A Unifying Mechanism. Diabetes 2005;54(6):1615-1625. Available from: http://diabetes.diabetesjournals.org/cgi/doi/10.2337/diabetes.54.6.1615 doi: 10.2337/diabetes.54.6.1615.

Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control. Journal of Diabetes and its Complications 2005;19(3):178-181. Available from: http://linkinghub.elsevier.com/retrieve/pii/S105687270400114X doi: 10.1016/j.jdiacomp.2004.10.001.

Brownlee M, Hirsch IB. Glycemic Variability: A Hemoglobin A 1c –Independent Risk Factor for Diabetic Complications. JAMA 2006;295(14):1707-1708. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.295.14.1707 doi: 10.1001/jama.295.14.1707.

Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23(5):644-649. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.23.5.644 doi: 10.2337/diacare.23.5.644.

Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism 2002;15(4):369-376.

Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, et al. Randomized Cross-Over Trial of Insulin Glargine Plus Lispro or NPH Insulin Plus Regular Human Insulin in Adolescents With Type 1 Diabetes on Intensive Insulin Regimens. Diabetes Care 2003;26(3):799-804. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.26.3.799 doi: 10.2337/diacare.26.3.799.

Schober E, Schoenle E, Dyk, J. Van , Wernicke-Panten K. Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents With Type 1 Diabetes. Diabetes Care 2001;24(11):2005-2006. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.24.11.2005 doi: 10.2337/diacare.24.11.2005.

Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus. The Journal of Pediatrics 2008;153(4):547-553. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022347608003697 doi: 10.1016/j.jpeds.2008.04.063.

Дедов ИИ, Петеркова ВА, Кураева ТЛ. Первый пролонгированный беспиковый аналог человеческого инсулина 24-часового действия гларгин (Лантус) в лечении сахарного диабета у детей и подростков. Методические рекомендации. М; 2004. 19 с.[ Dedov II, Peterkova VA, Kuraeva TL. Pervyy prolongirovannyy bespikovyy analog chelovecheskogo insulina 24-chasovogo deystviya glargin (Lantus) v lechenii sakharnogo diabeta u detey i podrostkov. Metodicheskie rekomendatsii. Moscow; 2004. 19 p.]

Дедов ИИ, Кураева ТЛ, Петеркова ВА, Емельянов АО. Инсулинотерапия сахарного диабета 1 типа: современная тактика профилактики сосудистых осложнений. Пособие для врачей. М; 2005. 61 с.[ Dedov II, Kuraeva TL, Peterkova VA, Emel'yanov AO. Insulinoterapiya sakharnogo diabeta 1 tipa: sovremennaya taktika profilaktiki sosudistykh oslozhneniy. Posobie dlya vrachey. Moscow; 2005. 61 p.]

Emelianov A, Kuraeva T, Cherbacheva L. Risk of nocturnal hypoglycemia in children with type 1 diabetes mellitus treated with insulin glargine. In: Abstracts of the 45th Annual Meeting of the European Society for Paediatric Endocrinology, Rotterdam, The Netherlands, June 30-July 3, 2006. Horm Res 2006;65(Suppl.4):205.

Goonetilleke R, Pollitzer M, Mann N. Insulin for toddlers with difficult diabetes. Diabetes Care 2004;27(6):1505. Available from: http://www.nlm.nih.gov/medlineplus/diabetestype1.html PubMed PMID: 15161809.

Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther 2003;5(5):801-806. Available from: http://www.nlm.nih.gov/medlineplus/diabetestype1.html PubMed PMID: 14633345. doi: 10.1089/152091503322527003.

Colino E, López-Capapé M, Golmayo L, Álvarez MA, Alonso M, Barrio R. Therapy with insulin glargine (Lantus®) in toddlers, children and adolescents with type 1 diabetes. Diabetes Research and Clinical Practice 2005;70(1):1-7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0168822705000410 doi: 10.1016/j.diabres.2005.02.004.

Danne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, et al. A randomized trial comparing the rate of hypoglycemia-assessed using continuous glucose monitoring-in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study. Pediatr Diabetes 2013;14(8):593-601. Available from: http://doi.wiley.com/10.1111/pedi.12051 doi: 10.1111/pedi.12051.

White NH, Chase HP, Arslanian S, Tamborlane WV. Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes. Diabetes Care 2009;32(3):387-393. Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc08-0800 doi: 10.2337/dc08-0800.

Fiallo-Scharer R. Eight-Point Glucose Testing Versus the Continuous Glucose Monitoring System in Evaluation of Glycemic Control in Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism 2005;90(6):3387-3391. Available from: http://press.endocrine.org/doi/abs/10.1210/jc.2004-2510 doi: 10.1210/jc.2004-2510.

The authors declare that there are no conflicts of interest present.